Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Consensus Target Price of $802.18 According to Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average recommendation of “Moderate Buy” from the twenty-six research firms that are covering the company, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $809.50.

REGN has been the subject of a number of research reports. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $735.20 on Wednesday. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a 50 day moving average price of $788.30 and a 200 day moving average price of $720.93. The stock has a market capitalization of $75.70 billion, a P/E ratio of 18.17, a PEG ratio of 1.41 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the company earned $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals will post 45.34 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 3,946 shares of company stock worth $3,302,458. Corporate insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently modified their holdings of the stock. Orbimed Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $11,358,000. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Contravisory Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $6,327,000. Oxbow Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $323,249,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi alliance expanded, with substantial upfront and milestone potential. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in additional milestones for four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s immunology pipeline beyond Dupixent. Sanofi pays Regeneron up to $8B to expand immunology alliance
• Positive Sentiment: Weight-loss combination data address a key GLP-1 concern. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of the muscle lost by patients receiving semaglutide alone in an MRI substudy. The result could give Regeneron a differentiated position in the obesity market, although additional development and regulatory work remain. Phase 2 COURAGE Trial results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions suggest improved confidence in the company’s pipeline and longer-term growth prospects.
• Neutral Sentiment: Ubamatamab showed promising but early oncology results. The therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset is encouraging but requires confirmation in larger studies. Ubamatamab ovarian cancer study
• Negative Sentiment: Investors appeared underwhelmed by the ovarian cancer data. Despite the high response rate, reports indicated that REGN came under pressure after the early-stage readout, likely reflecting concerns about the limited patient sample, durability, and the distance to possible approval.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.